tiprankstipranks
Iterum Therapeutics Announces CMO Transition and Consultant Role
Company Announcements

Iterum Therapeutics Announces CMO Transition and Consultant Role

Don't Miss our Black Friday Offers:

An update from Iterum Therapeutics Plc (ITRM) is now available.

Sailaja Puttagunta M.D. will step down as Chief Medical Officer of Iterum Therapeutics plc on May 31, 2024, for personal reasons, not due to any conflict with the firm. She will continue to assist as a consultant during the regulatory review of the company’s new drug application. Dr. Steven Aronin will take over her responsibilities in leading the company’s development and regulatory activities.

For an in-depth examination of ITRM stock, go to TipRanks’ Stock Analysis page.

Related Articles
TheFlyIterum Therapeutics regains full Nasdaq compliance
TipRanks Auto-Generated NewsdeskIterum Therapeutics’ Strategic Advances with ORLYNVAH Approval
TheFlyIterum Therapeutics reports Q3 non-GAAP EPS (24c) vs. ($1.20) last year
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App